Sheet

PTC/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless II contains a valid OMB

Complete if Known Substitute for form 1449B/PTO Application Number 10/073,065 INFORMATION DISCLOSURE Filing Date February 12, 2002 STATEMENT BY APPLICANT First Named Inventor Shyam S. Mohapatra Group Art Unit 1648 (uso as many sheets as necessary) Examiner Name Zachariah Lucas **Attorney Docket Number** USF-T156X of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Inițials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	λ,
32	R1	MAO, H.Q. et al. "DNA-chitosan nanospheres for gene delivery" in International Symposium on Controlled Release of Bioactive Materials, 23(1996), Kyoto, Japan, Controlled Release Society; abstract no. 4138, p. 401.	
22	R2	MAO, H.Q. et al. "DNA-chitosan nanospheres: derivatization and storage stability" in International Symposium on Controlled Release of Bloactive Materials, 24(1997), Stockholm, Sweden, Controlled Release Society, abstract no. 6016, p. 671.	
3 2	R3	WALSH, S.M. et al. "Combination of drug and gene delivery by gelatin nanospheres for the treatment of cystic fibrosis" in Proceedings of the International Conference on Controlled Release of Bioactive Agents, 24(1997), Stockholm, Sweden, abstract no. 238, p. 75.	
32	R4	TRUONG-LE, V.L. et al. "Delivery of DNA vaccine using gelatin-DNA nanospheres" in International Symposium on Controlled Release of Bioactive Materials, 24(1997), Stockholm, Sweden, Controlled Release Society, abstract no. 219, p. 39.	
32	- R5	ROY, K. et al. "DNA-chitosan nanospheres: transfection efficiency and cellular uptake" in International Symposium on Controlled Release of Bioactive Materials, 24(1997), Stockholm, Sweden, Controlled Release Society, abstract no. 6017, p. 673.	
	R6		
	R7		
	R8		
	R9		<u> </u>
	R10		-
	R11		-
	R12		-
1	R13	<b>)</b>	1

Examiner		Date	111-1
Signature	6 m	Completened	11/2/04
olgnature		Considered	111-101
EVALUATED Labor b	I reference approidered whether as not situlting in the second of the	TO BOO BY	and the state of t

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.99. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.